Clinical Evaluation of Platelet Concentrates Either in Plasma or in Additive Solution

Abstract

Background and Objectives. Platelet concentrates (PC) obtained from Buffy-Coat (BC) may be diluted in a platelet additive solution (PAS). These PCs may reduce plasma-related adverse reactions. We have tried to assess the relationship between PAS PCs and adverse reactions. Materials and Methods. During 6 months, patients treated with intensive chemotherapy, participated in a prospective study and were randomly assigned to receive, on a prophylactic basis, PCs in either plasma or PAS-2. Five iso-group BCs were pooled diluted in either plasma or PAS-2. One hour after each transfusion, corrected count increments (CCIs) were calculated, presence of hemorrhage and adverse reactions were recorded. Results. Platelet increment, 1-hour platelet count, and corrected count increments (CCI) after transfusion in both groups were similar. There were more transfusion-dependent adverse reactions in plasma group. Conclusion. Use of PAS-2 resulted in less transfusion related reactions; therefore, we recommend synthetic additive solutions to dilute PCs.

Platelet activation during storage of platelet concentrates processed from buffy coats by the automated OrbiSac system

“…Trying to think of how to reduce it, we realized that in our component laboratory the first event that increased activation was the implementation of a PLT additive solution (PAS) instead of plasma as storage medium for PCs. This change was not associated with clinical problems in patients; in contrast, the use of PAS‐2 (SSP, Macopharma, Tourcoing, France) resulted in fewer transfusion‐related reactions 4 . The effects on PLT metabolism and function associated with different components in PAS are only partly known, so we decided to test different ASs and compared them only in A‐PCs.…”